Saïd Business School
University of Oxford
Park End Street
Bernard has a PhD in science and technology in medicine and is a clinical pharmacist by profession.
Prior to Bernard’s academic career he worked as a specialist clinical pharmacist at Oxford University Hospitals NHS Foundation Trust where he still performs research and clinical work on a sessional basis. Bernard is also a member of the Royal Pharmaceutical Society of Great Britain and the Academy of Management.
Bernard’s research concerns leadership, health care and technology.
Bernard’s research examines supply chain traceability, major project leadership, responsible innovation and impact. Bernard’s current research project is funded by the Norwegian Research Council and concerns responsible innovation and the experiences of digital health firms. Bernard’s research is based within public sector organisations with a particular focus on health care.
- Supply Chain Traceability and Falsified Medicines
- Major Project Leadership and Impact
- Responsible Research and Innovation in Digital Health
- Organisational Stigma in Health Care
Medicine authentication technology: a quantitative study of incorrect quarantine, average response times and offline issues in a hospital setting.(opens in new window)
Responsible innovation and commercialisation in the university context: a case study of an academic entrepreneur in digital healthcare
Medicine authentication technology as a counterfeit medicine-detection tool: a Delphi method study to establish expert opinion on manual medicine authentication technology in secondary care.(opens in new window)
International Counterfeit Medicines Regulation
Effectiveness of medicines authentication technology to detect counterfeit, recalled and expired medicines: a two-stage quantitative secondary care study.(opens in new window)
Bernard performs consultancy work which aims to translate his research findings into practice.
Bernard aims to generate impact through engagement with external organisations including charities, NHS hospitals, professional and regulatory bodies, private technology firms, and pharmaceutical companies.